Literature DB >> 10607865

Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine.

M Shankaran1, B K Yamamoto, G A Gudelsky.   

Abstract

The mechanism of 3,4-methylenedioxymethamphetamine (MDMA)-induced depletion of brain serotonin (5-hydroxytryptamine, 5-HT) has been proposed to involve the generation of reactive oxygen species. In the present study, quantification of the extracellular concentration of 2,3-dihydroxybenzoic acid (2,3-DHBA) from salicylic acid was used as an index of hydroxyl radical generation. Although both MDMA and D-amphetamine markedly increased the extracellular concentration of dopamine in the striatum, only MDMA increased the extracellular concentration of 2,3-DHBA. Treatment with fluoxetine either 1 h prior to or 4 h following the administration of MDMA reduced the MDMA-induced formation of 2,3-DHBA and also attenuated the MDMA-induced depletion of 5-HT in the striatum. These results are supportive of the view that the MDMA-induced generation of hydroxyl radicals and, ultimately, the long-term depletion of 5-HT, is dependent, in part, on the activation of the 5-HT transporter.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10607865     DOI: 10.1016/s0014-2999(99)00728-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  29 in total

1.  Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity.

Authors:  T Xie; U D McCann; S Kim; J Yuan; G A Ricaurte
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions.

Authors:  Joseph M Breier; Michael G Bankson; Bryan K Yamamoto
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

Review 3.  Causes and consequences of methamphetamine and MDMA toxicity.

Authors:  Maria S Quinton; Bryan K Yamamoto
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

4.  Concurrent Inhibition of Vesicular Monoamine Transporter 2 Does Not Protect Against 3,4-Methylenedioxymethamphetamine (Ecstasy) Induced Neurotoxicity.

Authors:  Aram B Cholanians; Andy V Phan; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

5.  Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain.

Authors:  María Izco; Laura Orio; Esther O'Shea; M Isabel Colado
Journal:  Psychopharmacology (Berl)       Date:  2006-10-18       Impact factor: 4.530

6.  A novel nitroxide is an effective brain redox imaging contrast agent and in vivo radioprotector.

Authors:  Ryan M Davis; Anastasia L Sowers; William DeGraff; Marcelino Bernardo; Angela Thetford; Murali C Krishna; James B Mitchell
Journal:  Free Radic Biol Med       Date:  2011-05-25       Impact factor: 7.376

7.  A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons.

Authors:  Laura Orio; Noemi Llopis; Elisa Torres; Maria Izco; Esther O'Shea; M Isabel Colado
Journal:  Neurotox Res       Date:  2009-09-24       Impact factor: 3.911

8.  Effect of repeated exposure to MDMA on the function of the 5-HT transporter as assessed by synaptosomal 5-HT uptake.

Authors:  Courtney Huff; Nirmal Bhide; Allen Schroering; Bryan K Yamamoto; Gary A Gudelsky
Journal:  Brain Res Bull       Date:  2013-01-12       Impact factor: 4.077

9.  Effects of adenosine A2a receptor agonist and antagonist on hippocampal nuclear factor-kB expression preceded by MDMA toxicity.

Authors:  Fatemeh Kermanian; Mansooreh Soleimani; Alireza Ebrahimzadeh; Hossein Haghir; Mehdi Mehdizadeh
Journal:  Metab Brain Dis       Date:  2012-12-06       Impact factor: 3.584

Review 10.  Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-10-16       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.